期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Serendipity in anticancer drug discovery
1
作者 emily hargrave-thomas Bo Yu Jóhannes Reynisson 《World Journal of Clinical Oncology》 CAS 2012年第1期1-6,共6页
It was found that the discovery of 5.8%(84/1437) of all drugs on the market involved serendipity. Of these drugs, 31(2.2%) were discovered following an incident in the laboratory and 53(3.7%) were discovered in a clin... It was found that the discovery of 5.8%(84/1437) of all drugs on the market involved serendipity. Of these drugs, 31(2.2%) were discovered following an incident in the laboratory and 53(3.7%) were discovered in a clinical setting. In addition, 263(18.3%) of the pharmaceuticals in clinical use today are chemical derivatives of the drugs discovered with the aid of serendipity. Therefore, in total, 24.1%(347/1437) of marketed drugs can be directly traced to serendipitous events confirming the importance of this elusive phenomenon. In the case of anticancer drugs, 35.2%(31/88) can be attributed to a serendipitous event, which is somewhat larger than for all drugs. The therapeutic field that has benefited the most from serendipity are central nervous system active drugs reflecting the difficulty in designing compounds to pass the blood-brain-barrier and the lack of laboratory-based assays for many of the diseases of the mind. 展开更多
关键词 ANTICANCER DRUGS DRUG DISCOVERY and DEVELOPMENT Serendipity
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部